Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
Clinical trial NCT03509545 · TERMINATED
Trial details
- NCT number
- NCT03509545
- Sponsor
- Sarfez Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-30
- Primary completion
- 2022-06-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.